pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
Endpoints·55m ago·1 min read
save

Hims launches popular peptides and other longevity treatments

Nov 18, 2026·read at Endpoints ↗

Hims & Hers started offering peptides and other treatments marketed for longevity and wellness uses on Wednesday. But the telehealth company is holding off on prescribing some of the more controversial peptides that compounding pharmacies ...

source

Reporting by Endpoints.

read at Endpoints ↗
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

no entities indexed yet

related stories

  • 1h agoNovo’s consumer push gains momentum with Wegovy pill, CagriSema on deckEndpoints
  • 3h ago#CTAD26: Lilly’s dopamine drug mevidalen fails Phase 2 study in Alzheimer’sEndpoints
  • 4h agoDispatches from Jefferies: Latent Labs on AI, Relay’s PI3Kα ambitions and Biohaven’s protein degrader approachEndpoints
  • 7h agoPfizer gets into in vivo CAR-T through licensing deal with Starna TherapeuticsEndpoints
  • 8h agoAI bio startup Boltz raises $110M Series AEndpoints